233 related articles for article (PubMed ID: 29483215)
1. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
[TBL] [Abstract][Full Text] [Related]
2. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
Lee JY; Lee I; Chang WJ; Ahn SM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Cho JH; Kim SY; Kim KM; Lee S; Kim ST; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
Oncotarget; 2016 Jul; 7(28):43492-43503. PubMed ID: 27224918
[TBL] [Abstract][Full Text] [Related]
3. Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
Gotanda Y; Akagi Y; Kawahara A; Kinugasa T; Yoshida T; Ryu Y; Shiratsuchi I; Kage M; Shirouzu K
Anticancer Res; 2013 Jul; 33(7):2941-7. PubMed ID: 23780984
[TBL] [Abstract][Full Text] [Related]
4. A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer.
Saito T; Kurashige J; Nambara S; Komatsu H; Hirata H; Ueda M; Sakimura S; Uchi R; Takano Y; Shinden Y; Iguchi T; Eguchi H; Ehata S; Murakami K; Sugimachi K; Mimori K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S915-22. PubMed ID: 25986864
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas.
Pinheiro C; Longatto-Filho A; Scapulatempo C; Ferreira L; Martins S; Pellerin L; Rodrigues M; Alves VA; Schmitt F; Baltazar F
Virchows Arch; 2008 Feb; 452(2):139-46. PubMed ID: 18188595
[TBL] [Abstract][Full Text] [Related]
7. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
[TBL] [Abstract][Full Text] [Related]
8. High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer.
Yan P; Li YH; Tang ZJ; Shu X; Liu X
Asian Pac J Cancer Prev; 2014; 15(20):8923-9. PubMed ID: 25374230
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner.
Lim KS; Lim KJ; Price AC; Orr BA; Eberhart CG; Bar EE
Oncogene; 2014 Aug; 33(35):4433-41. PubMed ID: 24077291
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma.
Kim JH; Bae JM; Song YS; Cho NY; Lee HS; Kang GH
Oncotarget; 2016 Mar; 7(12):13372-87. PubMed ID: 26528695
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma.
Cheng B; Chen X; Li Y; Huang X; Yu J
Oncol Rep; 2018 Nov; 40(5):2906-2915. PubMed ID: 30226548
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of the expression of monocarboxylate transporter 4 in patients with right- or left-sided colorectal cancer.
Abe Y; Nakayama Y; Katsuki T; Inoue Y; Minagawa N; Torigoe T; Higure A; Sako T; Nagata N; Hirata K
Asia Pac J Clin Oncol; 2019 Apr; 15(2):e49-e55. PubMed ID: 30270512
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
[TBL] [Abstract][Full Text] [Related]
14. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.
Baenke F; Dubuis S; Brault C; Weigelt B; Dankworth B; Griffiths B; Jiang M; Mackay A; Saunders B; Spencer-Dene B; Ros S; Stamp G; Reis-Filho JS; Howell M; Zamboni N; Schulze A
J Pathol; 2015 Oct; 237(2):152-65. PubMed ID: 25965974
[TBL] [Abstract][Full Text] [Related]
15. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
16. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells.
Amorim R; Pinheiro C; Miranda-Gonçalves V; Pereira H; Moyer MP; Preto A; Baltazar F
Cancer Lett; 2015 Aug; 365(1):68-78. PubMed ID: 26021766
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells.
Diehl K; Dinges LA; Helm O; Ammar N; Plundrich D; Arlt A; Röcken C; Sebens S; Schäfer H
Oncogene; 2018 Jan; 37(1):39-51. PubMed ID: 28846107
[TBL] [Abstract][Full Text] [Related]
18. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.
Choi SY; Xue H; Wu R; Fazli L; Lin D; Collins CC; Gleave ME; Gout PW; Wang Y
Clin Cancer Res; 2016 Jun; 22(11):2721-33. PubMed ID: 26755530
[TBL] [Abstract][Full Text] [Related]
19. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
[TBL] [Abstract][Full Text] [Related]
20. POLR1D promotes colorectal cancer progression and predicts poor prognosis of patients.
Wang M; Niu W; Hu R; Wang Y; Liu Y; Liu L; Zhong J; Zhang C; You H; Zhang J; Lu L; Wei L; Xiao W
Mol Carcinog; 2019 May; 58(5):735-748. PubMed ID: 30582221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
